04.09.2025
The Government and Danish Regions have launched a new strategy for personalised medicine with 13 concrete initiatives designed to ensure that patients receive more accurate diagnoses and tailored treatments. The aim is to avoid overtreatment, reduce side effects, and prevent unnecessary hospitalisations.
Pharmadanmark’s Chair, Stine Hasling Mogensen, highlights the importance of leveraging Denmark’s strong position in health data and biobanks across sectors, to benefit both patients and research – and not least the opportunities offered by artificial intelligence in this field:
“I am particularly pleased to see that Denmark’s unique health data will be used to ensure earlier detection and individualised treatment pathways for each patient – based on their life situation, wishes, and values,” says Stine Hasling Mogensen.
“As a pharmacist, I am also excited that the strategy supports the development of pharmacogenetic analysis methods and proposes examining the opportunities and challenges of establishing pharmacogenetic profiles. This is an area where countries such as Finland and the Netherlands are ahead of Denmark, and where it is vital that we make use of existing technologies to ensure patients receive individualised treatments with the fewest possible side effects.”
With this strategy, Denmark aims to position itself as a European leader in developing, testing – and, importantly – delivering advanced therapies, ensuring patients faster access to the most innovative solutions.
Pharmadanmark welcomes this ambition and believes it could be of decisive importance for people with rare diseases.